Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on January 25, 2021. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The filing discloses a new debt obligation and the issuance of unregistered equity securities.
Key Financial Metrics
- New Debt Obligation: Borrowed an additional $1.0 million under a Secured Convertible Facility Agreement with Juvenescence Limited.
- Repayment Date: The outstanding principal balance is due on March 30, 2023.
- Equity Issuance: Issued warrants to purchase 263,852 shares of common stock.
- Warrant Exercise Price: $1.895 per share.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, profit, cash flow, margins, or total liquidity.
Material Changes
The primary material change reported is the drawdown of $1.0 million in credit facilities on January 25, 2021. This transaction increased the company's debt load and resulted in the issuance of unregistered warrants to the lender, Juvenescence Limited, as part of the loan agreement terms.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The company includes standard disclaimers that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
Events of Default: The New Loan Agreement contains extensive default provisions. Juvenescence may declare the loan immediately due if AgeX fails to pay within 10 business days, fails to perform obligations, incurs other indebtedness over specific thresholds ($100,000 or $25,000 depending on terms), becomes insolvent, or if a material adverse change occurs in financial condition. Other triggers include the loss of collateral, invalidity of security interests, or cessation of business.
Unregistered Securities: The warrants were issued without registration under the Securities Act of 1933, relying on exemptions under Section 4(a)(2) and Regulation S.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Secured Convertible Facility Agreement following this $1.0 million draw.
- Confirm the listing status of the 263,852 warrants on the NYSE American.
- Review the full text of the Warrant Agreement and Security Agreement filed as exhibits to the 2020 Form 10-K and 2020 Form 10-Q.
- Assess the company's current liquidity position against the March 30, 2023 repayment deadline.
- Monitor for any potential "Events of Default" related to other indebtedness or financial condition changes.